Achaogen Inc AKAOQ:OTC Pink - Limited Information

Last Price$0.0211NASDAQ Last Trade (15-minute delayed) as of 1:28PM ET 6/17/19
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change+0.001(5.45%)
Bid (Size)$0.02 (10,000)
Ask (Size)$0.02 (142,367)
Day Low / High$0.019 - 0.023
Volume240.8 K

Read more news Recent News

Achaogen Shares Dive 66%, Files for Chapter 11 Bankruptcy
12:46PM ET 4/15/2019 MT Newswires

Achaogen (AKAO) shares were 65% lower Monday morning after the company said it has filed a voluntary petition under Chapter 11 of the Bankruptcy Code in a...

Insider Trends: Selling By Insiders Lingers at Achaogen
5:27PM ET 3/20/2019 MT Newswires

On Mar 18, 2019, 10% Owner, Robert W Duggan, executed a sale of 1,277,888 shares in Achaogen (AKAO) for $685,437. After the Form 4 filing with the SEC,...

Significant Insider Selling in Shares of Achaogen (AKAO) Continues
10:17PM ET 3/14/2019 MT Newswires

A SEC filing today indicated a substantial insider sale of Achaogen shares as -- Robert W Duggan, 10% Owner -- disposed of 2,354,007 shares in the company...

Insider Trends: Insider Adds to Selling Trend at Achaogen
5:34PM ET 3/13/2019 MT Newswires

Robert W Duggan, 10% Owner, on Mar 11, 2019, sold 2,354,007 shares in Achaogen (AKAO) for $1,422,348. Duggan, subsequent to the transactions disclosed in...

View all Commentary and Analysis

Scynexis And The Fungal Economy
32 minutes ago, 1:14PM ET 6/17/2019 Seeking Alpha

Melinta: Can This Antibiotic Innovator Overcome Industry Headwinds?
11:59AM ET 5/20/2019 Seeking Alpha

Melinta Therapeutics: Undervalued And Underappreciated In 2019
5:56PM ET 4/30/2019 Seeking Alpha

Achaogen, Inc. (AKAO) CEO Blake Wise on Q4 2018 Results - Earnings Call Transcript
9:08PM ET 3/28/2019 Seeking Alpha

Company Profile

Business DescriptionAchaogen, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of antibacterial treatments for multi-drug resistant (MDR) gram-negative infections. It offers Plazomicin to treat bacterial illness, such as complicated urinary tract infection, blood stream infections, and other infections due to MDR Enterobacteriaceae. The company was founded by Nathaniel E. David in June 2002 and is headquartered in South San Francisco, CA. View company web site for more details
Address1 Tower Place
South San Francisco, California 94080
Number of Employees42
Recent SEC Filing06/07/20198-K
Chief Executive Officer, CFO, CAO & DirectorBlake Wise
Chief Operating & Business OfficerLiz Bhatt
Chief Compliance Officer & General CounselGary H. Loeb
Chief Commercial OfficerJanet Dorling

Company Highlights

Price Open$0.02
Previous Close$0.02
52 Week Range$0.02 - 13.48
Market Capitalization$1.3 M
Shares Outstanding63.9 M
SectorHealth Technology
IndustryPharmaceuticals: Other
Next Earnings Announcement06/21/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$3.92
Beta vs. S&P 500N/A
Revenue$8.7 M
Net Profit Margin-2,136.94%
Return on Equity-354.40%

Analyst Ratings as of 06/07/2019

Consensus RecommendationConsensus Icon
Powered by Factset